IRF3 and obesity disorder: This study has two primary limitations: (1) exclusive use of JTTZF decoction without exploring active constituents' efficacy; (2) insufficient understanding of JTTZF‐modulated cGAS function in obesity‐related diabetes, requiring future validation; (3) IRF3 phosphorylation may exhibit strict time and dose dependence in the cGAS‐STING pathway.